RT Journal Article
T1 The Multicompartmental p32/gClqR as a New Target for Antibody-based Tumor Targeting Strategies
A1 Sánchez-Martín, David
A1 Fogal, Valentina
A1 Ruoslahti, Erkki
A1 Álvarez-Vallina, Luis
A1 Cuesta Martínez, Ángel
AB Tumor-associated cell surface antigens and tumor-associated vascular markers have been used as a target for cancer intervention strategies. However, both types of targets have limitations due to accessibility, low and/or heterogeneous expression, and presence of tumor-associated serum antigen. It has been previously reported that a mitochondrial/cell surface protein, p32/gC1qR, is the receptor for a tumor-homing peptide, LyP-1, which specifically recognizes an epitope in tumor cells, tumor lymphatics, and tumor-associated macrophages/myeloid cells. Using antibody phage technology, we have generated an anti-p32 human monoclonal antibody (2.15). The 2.15 antibody, expressed in single-chain fragment variable and in trimerbody format, was then characterized in vivo using mice grafted subcutaneously with MDA-MB-231 human breast cancers cells, revealing a highly selective tumor uptake. The intratumoral distribution of the antibody was consistent with the expression pattern of p32 in the surface of some clusters of cells. These results demonstrate the potential of p32 for antibody-based tumor targeting strategies and the utility of the 2.15 antibody as targeting moiety for the selective delivery of imaging and therapeutic agents to tumors.
SN 0021-9258
YR 2011
FD 2011-02-01
LK https://hdl.handle.net/20.500.14352/93792
UL https://hdl.handle.net/20.500.14352/93792
LA eng
NO Sánchez-Martín D, Cuesta AM, Fogal V, Ruoslahti E, Alvarez-Vallina L. The multicompartmental p32/gClqR as a new target for antibody-based tumor targeting strategies. J Biol Chem. 2011;286(7):5197-5203. doi:10.1074/jbc.M110.161927
NO Ministerio de Ciencia e Innovación
NO Comunidad Autónoma de Madrid
NO European Union
NO U. S. Department of Defense Breast Cancer Program
NO Susan Komen Foundation
DS Docta Complutense
RD 20 ago 2024